Migdal Insurance & Financial Holdings Ltd. Nurix Therapeutics, Inc. Transaction History

Migdal Insurance & Financial Holdings Ltd.

$6.18 Billion
Q3 2024

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 02, 2022	SELL	$12.94 - $29.65 $4,800 - $11,000	-371 Closed	0 $0
Q4 2021 Feb 02, 2022	SELL	$26.43 - $34.5 $5,920 - $7,728	-224 Reduced 37.65%	371 $11,000
Q3 2021 Nov 16, 2021	BUY	$22.71 - $36.69 $13,512 - $21,830	595 New	595 $18,000

Others Institutions Holding NRIX

# of Institutions

181

Shares Held

68.1M

Call Options Held

78K

Put Options Held

53.8K

Black Rock Inc. New York, NY

6.82M
Shares

$149 Million
0.0% of portfolio
Redmile Group, LLC San Francisco, CA

4.28M
Shares

$93.3 Million
6.28% of portfolio
Vanguard Group Inc Valley Forge, PA

4.01M
Shares

$87.4 Million
0.0% of portfolio
Baker Bros. Advisors LP New York, NY

3.88M
Shares

$84.6 Million
0.93% of portfolio
Deep Track Capital, LP Greenwich, CT

3.87M
Shares

$84.3 Million
3.2% of portfolio

View Full List

About Nurix Therapeutics, Inc.

Ticker NRIX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,147,800
Market Cap $1.03B
Description
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...

More about NRIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Migdal Insurance & Financial Holdings Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Migdal Insurance & Financial Holdings Ltd. with notifications on news.

Account